Content area

|
|

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Forfatter(e)
Annika Loft & Andreas Kjær Klinik for Klinisk Fysiologi, Nuklearmedicin & PET og Cluster for Molecular Imaging, Rigshospitalet

Ugeskr Læger 2018;180:V06180463
Reference: 
Ugeskr Læger 2018;180:V06180463
Blad nummer: 
Sidetal: 

Annika Loft & Andreas Kjær:

Nuclear medical diagnostic and cancer precision medicine

Ugeskr Læger 2018;180:V06180463

Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Knud Gade Freund | 01/04
2 kommentarer
af Knud Erik Alsbirk | 30/03
1 Kommentar
af Andreas Schröder | 29/03
1 Kommentar
af Steen Frobenius | 29/03
4 kommentarer
af Louise Vang Christensen | 29/03
5 kommentarer
af Rune Jacobsen | 28/03
15 kommentarer
af Peter Hering Østrup | 27/03
4 kommentarer
af Niels Emil Ulrich Hermansen | 27/03
3 kommentarer